H2 receptor antagonist clinical trials
3 indexed studies · 2 currently recruiting
- RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
For: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
This study looks at a new drug, sacituzumab tirumotecan, for people with a type of lung cancer (non-small cell lung cancer) that has specific genetic changes and has worsened after previous treatments. It compares this new drug to a standard chemotherapy combination to see if it improves survival.
For: Non-small Cell Lung Cancer (NSCLC)United States · Argentina · Canada - RecruitingPHASE1
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
This study is testing a new drug, OKN4395, alone and with an existing cancer treatment, pembrolizumab, for various solid tumours. The main goals are to check its safety, how well it's tolerated, and if it helps fight cancer.
For: Solid Tumours · Sarcoma · HNSCCUnited States · Australia · United Kingdom